Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Experimental drug for IBS falls flat in dose-ranging trial

25 Jan 2025

The novel α2δ ligand PD-217,014 does not appear to show any benefit in the treatment of patients with irritable bowel syndrome (IBS) or bowel habit subtypes, irrespective of their pain and anxiety levels, according to a study.

Experimental drug for IBS falls flat in dose-ranging trial

25 Jan 2025

IBD patients prone to develop COPD, asthma

24 Jan 2025 bởi

Individuals with inflammatory bowel disease (IBD) appear to be at greater risk of developing chronic obstructive pulmonary disease (COPD) and asthma, suggests a study.

IBD patients prone to develop COPD, asthma

24 Jan 2025

One monoclonal antibody outdoes another in real-world ulcerative colitis study

22 Jan 2025 bởi

The integrin receptor antagonist vedolizumab mostly works as well as the TNF-alpha inhibitor infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis treated in the real-world setting, although vedolizumab slightly surpasses infliximab in terms of inducing endoscopic response and remission while having a better safety profile, according to a study.

One monoclonal antibody outdoes another in real-world ulcerative colitis study

22 Jan 2025

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025 bởi

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025

Gallstone disease ups IBD risk

20 Jan 2025

People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.

Gallstone disease ups IBD risk

20 Jan 2025

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025 bởi

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

Pregnant women with inflammatory bowel disease (IBD) who used antitumour necrosis factor (anti-TNF) therapy are at reduced risk of developing gestational diabetes mellitus (GDM), reports a study.

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025 bởi

Inflammatory bowel disease (IBD) is associated with an increased risk of hidradenitis suppurativa (HS), according to a study presented at AIBD 2024.

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025 bởi

Mirikizumab helps improve health-related quality of life (HRQoL) in Crohn’s disease (CD) patients, including those who have not had success with a biologic therapy, according to data from the phase III VIVID-1 study.

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025 bởi

Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025

Tin tức & Cập nhật

Xem bài viết Tiêu hóa

Xem

Chuyên ngành:

Experimental drug for IBS falls flat in dose-ranging trial

Experimental drug for IBS falls flat in dose-ranging trial

IBD patients prone to develop COPD, asthma

IBD patients prone to develop COPD, asthma

One monoclonal antibody outdoes another in real-world ulcerative colitis study

One monoclonal antibody outdoes another in real-world ulcerative colitis study

No increase in CV risk with JAKi vs TNFi for IBD

No increase in CV risk with JAKi vs TNFi for IBD

Gallstone disease ups IBD risk

Gallstone disease ups IBD risk

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Anti-TNFs may reduce GDM risk in pregnant women with IBD

Anti-TNFs may reduce GDM risk in pregnant women with IBD

IBD linked to increased risk of hidradenitis suppurativa

IBD linked to increased risk of hidradenitis suppurativa

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?